Baxter International Inc. · NYSE:BAX
Baxter International — Q2 2019 Earnings Presentation
11 slides from Baxter International's earnings presentation, Jul 25, 2019
Slide 1: Non-GAAP Reconciliation as of July 25, 2019
Non-GAAP Reconciliation as of July 25, 2019 Non-GAAP Reconciliations: As part of its Q2 2019 earnings announcement on July 25, 2019, Baxter presented its financial results for Q2 2019, Q2 2018, and the related year to date periods. Baxter also presented guidance for Q3 2019 and FY 2019. In these pre
Slide 2: Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures
Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures Three Months Ended June 30, 2019 and 2018 (unaudited) (in millions, except per share and percentage data) The company's GAAP results for the three months ended June 30, 2019 and 2018 included special items which impacted the
Slide 3: Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures
Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures Three Months Ended June 30, 2019 and 2018 (unaudited) 1 The company's results in 2019 and 2018 included intangible asset amortization expense of $45 million ($35 million, or $0.07 per diluted share, on an after-tax basis) and
Slide 4: Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures
Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures Six Months Ended June 30, 2019 and 2018 (unaudited) (in millions, except per share and percentage data) The company's GAAP results for the six months ended June 30, 2019 and 2018 included special items which impacted the GAAP
Slide 5: Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures
Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures Six Months Ended June 30, 2019 and 2018 (unaudited) 1 The company's results in 2019 and 2018 included intangible asset amortization expense of $88 million ($68 million, or $0.13 per diluted share, on an after-tax basis) and $
Slide 6: Reconciliation of Non-GAAP Financial Measure Change in Net Sales As Reported to Operational Sales
Reconciliation of Non-GAAP Financial Measure Change in Net Sales As Reported to Operational Sales From The Three Months Ended June 30, 2018 to The Three Months Ended June 30, 2019 (unaudited) Sales By Global Business Unit1: Q2 2 0 1 9 N et Sales U.S. Operational As Reported C yclophospham ide FX Sal
Slide 7: Reconciliation of Non-GAAP Financial Measure Change in Net Sales As Reported to Operational Sales
Reconciliation of Non-GAAP Financial Measure Change in Net Sales As Reported to Operational Sales From The Six Months Ended June 30, 2018 to The Six Months Ended June 30, 2019 (unaudited) Sales By Global Business Unit1: Y TD 2 0 1 9 N et Sales U.S. Operational As Reported C yclophospham ide FX Sales
Slide 8: Adjusted Selling, General and Administrative Expense and Adjusted Research and Development Expense
Adjusted Selling, General and Administrative Expense and Adjusted Research and Development Expense From The Three Months Ended June 30, 2018 to The Three Months Ended June 30, 2019 (unaudited) On Page 2, the GAAP Selling, General and Administrative Expense (SG&A) has been reconciled to the adjusted
Slide 9: Reconciliations for Q3 2019 and FY 2019 Forecasts
Non-GAAP Reconciliation as of July 25, 2019 Reconciliations for Q3 2019 and FY 2019 Forecasts The reconciliations between the projected 2019 GAAP sales growth and projected adjusted sales growth follows: 2019 Sales Growth Guidance Q3 2019 F Y 2019 Sales Growth – GAAP 3% - 4% 1% - 2% U.S. cyclophosph
Slide 10: Reconciliations for Q3 2019 and FY 2019 Forecasts
Non-GAAP Reconciliation as of July 25, 2019 Reconciliations for Q3 2019 and FY 2019 Forecasts The reconciliations between the projected 2019 GAAP operating margin and projected adjusted operating margin follows: 2 0 1 9 Operating M argin Guidance FY 2019 Operating M argin - GAAP 1 4 .9 % - 1 5 .4 %
Slide 11: Reconciliations for Q3 2019 and FY 2019 Forecasts
Non-GAAP Reconciliation as of July 25, 2019 Reconciliations for Q3 2019 and FY 2019 Forecasts The company’s outlook for GAAP earnings per share only includes the impact of special items that are known or expected as of the date of this release. Accordingly, actual GAAP earnings per share for the thi